Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-Current Deffered Revenue (2020 - 2026)

Cytek Biosciences filings provide 6 years of Non-Current Deffered Revenue readings, the most recent being $18.3 million for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue rose 13.92% to $18.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.3 million, a 13.92% increase, with the full-year FY2025 number at $18.3 million, up 13.92% from a year prior.
  • Non-Current Deffered Revenue hit $18.3 million in Q4 2025 for Cytek Biosciences, up from $16.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $18.3 million in Q4 2025 to a low of $6.3 million in Q2 2021.
  • Median Non-Current Deffered Revenue over the past 5 years was $14.8 million (2024), compared with a mean of $13.3 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 183.28% in 2021 and later decreased 12.4% in 2024.
  • Cytek Biosciences' Non-Current Deffered Revenue stood at $9.8 million in 2021, then soared by 34.06% to $13.1 million in 2022, then grew by 15.3% to $15.1 million in 2023, then grew by 6.38% to $16.1 million in 2024, then rose by 13.92% to $18.3 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $18.3 million (Q4 2025), $16.3 million (Q3 2025), and $16.6 million (Q2 2025) per Business Quant data.